Patient Oriented Research In Clinical Nutrition

描述(由申请人提供)：这份竞争续签申请的是以患者为中心的研究(K24)职业生涯中期研究人员奖“临床营养学以患者为中心的研究”，旨在为一位有成就的医生营养专家和临床和转化营养科学方面的知名研究人员提供支持。P.I.仍然高度致力于开展以患者为中心的研究(POR)，专注于营养，并指导临床营养研究的本科生、研究生和医学生、博士后研究员、临床住院医师和初级教员，以继续培养所需的、训练有素的临床营养研究人员的新干部。这项提议的更新将提供受保护的时间，使私人侦探能够继续推进他在营养导向研究方面的研究和指导工作，并在最先进的代谢组学方法方面提供额外的培训和资源，这反过来将增强他指导医生和其他临床研究人员的能力 与营养相关的研究。申请者在营养和医学方面有独特的培训背景，并在联邦、基金会和行业为他的研究人员发起的POR和翻译研究提供资金方面有着出色的记录。他保持着强劲且不断增长的出版记录，继续从NIH和其他来源为POR提供独立资金，继续在国家营养相关学会担任领导职务，并在以营养为导向的一线研究期刊的编辑委员会中提供更多服务。在Emory，P.I.担任由NIH资助的CTSA资助的亚特兰大临床和翻译科学研究所(ACTSI)的领导，包括ACTSI研究教育、培训和职业发展(RETCD)计划的联合计划主任，ACTSI/RETCD KL2博士后培训资助的联合计划主任，以及ACTSI/RETCD TL1博士后培训资助的计划主任(TL1 RR025010)。他在临床和分子营养中心担任领导职务，提供多项T32培训资助，以及埃默里营养与健康科学研究生项目-所有这些都为POR提供了继续指导的机会。自从K24基金的最初资助(07/01/07)以来，P.I.已经指导了32名受训者的临床/翻译研究活动，从本科生到初级教员，包括分别来自埃默里医学系和儿科系的目前的3名内科初级教员、2名博士生初级教员、4名来自前苏联共和国的国际内科研究员、3名内科博士后研究员、4名博士后研究员、1名临床营养支持的药学博士专家；3名埃默里大学博士研究生(2名营养与健康科学专业，1名护理专业)和1名埃默里大学本科生。候选人的POR计划为当前和潜在的受训者提供了丰富的培训基础，包括利用ACTSI进行的关于谷氨酰胺在分解代谢状态下的疗效和代谢影响的研究，包括危重护理、短肠综合征和囊性纤维化。镰状细胞性贫血，饮食相关的氧化还原控制和代谢组学分析。

DESCRIPTION (provided by applicant): This competing renewal application for the Midcareer Investigator Award in Patient Oriented Research (K24) "Patient-Oriented Research in Clinical Nutrition" seeks support for an accomplished physician nutrition specialist and established investigator in clinical and translational nutrition science. The P.I. remains highly committed to performing patient-oriented research (POR), focused on nutrition, and in mentoring undergraduates, graduate and medical students, postdoctoral fellows, clinical residents, and junior faculty in clinical nutrition research to continue to develop a needed new cadre of well-trained investigators in Clinical Nutrition. Renewal of this proposal will provide protected time t enable the P.I. to continue to advance his research and mentoring efforts in nutrition-oriented research, and provide additional training and resources in state-of-the-art metabolomics methods that will in turn enhance his ability to mentor physicians and other clinical investigators in nutrition-related studies. The applicant has a unique training background in nutrition and medicine and an excellent record of federal, foundation and industry funding for his investigator-initiated POR and translational research. He maintains a strong and growing publication record, renewed independent funding for POR from NIH and other sources, a continued history of leadership roles in national nutrition- related societies, and increasing service on the editorial boards of front-line nutrition-oriented research journals. At Emory, the P.I. serves in the leadership of the NIH-funded CTSA grant, the Atlanta Clinical and Translational Science Institute (ACTSI), including as Co-Program Director of the ACTSI Research Education, Training and Career Development (RETCD) program, Co-Program Director of the ACTSI/RETCD KL2 postdoctoral training grant, and Program Director of the ACTSI/RETCD TL1 predoctoral training grant (TL1 RR025010). He serves in leadership roles with the Center for Clinical and Molecular Nutrition, several T32 training grants and the Emory graduate program in Nutrition and Health Science - all of which provide opportunities for continued mentoring in POR. Since the initial funding of this K24 grant (07/01/07), the P.I. has mentored the clinical/translational research activities of 32 trainees, from the level of undergraduate student to junior faculty, including a current cadre of 3 physician junior faculty members from the Emory Departments of Medicine and Pediatrics, respectively; 2 Ph.D. junior faculty investigators; 4 international physician investigators from the former Soviet Republic of Georgia; 3 physician postdoctoral fellows; 4 Ph.D.-trained postdoctoral fellows; a Pharm.D. specialist in clinical nutrition support; 3 Emory Ph.D. graduate students (2 in Nutrition and Health Sciences and 1 in Nursing) and an Emory undergraduate student. The candidate's POR program provides a rich training substrate for current and potential mentees and includes ACTSI-leveraged studies on the efficacy and metabolic impact of glutamine in catabolic states, including critical care, short bowel syndrome, cystic fibrosis. sickle cell anemia, diet-related redox control and metabolomics analysis.